Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination oral rinse formulation consists of 0.09% chlorhexidine digluconate, Citrox (a proprietary bioflavonoid complex derived from *Citrus aurantium amara*), and hyaluronic acid. Developed for post-surgical oral care in patients with periodontitis, the formulation leverages the broad-spectrum antiseptic properties of chlorhexidine alongside the synergistic antimicrobial and antioxidant effects of citrus bioflavonoids. The inclusion of hyaluronic acid is intended to promote tissue regeneration and accelerate wound healing in the post-surgical phase. This specific combination, often marketed under the Curaprox Perio Plus+ line, aims to maintain high clinical efficacy in plaque control and gingival health while minimizing common chlorhexidine side effects such as tooth staining and taste alteration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + Citrus aurantium amara extract + hyaluronic acid.